REC Ref.	IRAS No.	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
17/LO/0401	217921	An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Combination with Sofosbuvir and Ribavirin in Chronic Hepatitis C (HCV) Infected Subjects Who Have Experienced Virologic Failure in AbbVie HCV Clinical Studies.	Number Agreed	1	1	Date Agreed	09/02/2018	1	23/06/2017	1	Recruitment Finished
16/LO/1984	215378	A Phase 2, Open-Label Clinical Trial to Study the Efficacy and Safety of 12 weeks of the Combination Regimen of MK-3682 + MK-8408 in Subjects with Chronic Hepatitis C Virus (HCV) Genotype 1, 2, 3, 4, 5 or 6 Infection	Number Agreed	4	4	Date Agreed	10/03/2017	5	29/03/2017	5	Recruitment Finished
16/SC/0441	209391	A Phase 1, First-in-Humans, randomized, double-blind (within dose level),placebo-controlled trial to evaluate the safety and immunogenicity of two intranasal doses of SynGEM®, an intranasal Respiratory Syncytial Virus (RSV) subunit candidate vaccine	Number Agreed	48	48	Date Agreed	25/01/2017	48	27/01/2017	48	Recruitment Finished
15/NW/0385	180668	A Four-Part Phase-1 Study Investigating the Tolerability, Safety and Pharmacokinetics (PK) of MBS2320 following Ascending Single and Multiple Oral Doses in Healthy Subjects and Multiple Oral Doses in Subjects with Rheumatoid Arthritis (RA) Also Treat	Number Agreed	2	7	Date Agreed	21/10/2017	4	23/03/2017	4	Recruitment Finished
16/LO/0586	200579	An Open Label Study to Evaluate the Efficacy and Safety of Ocrelizumab in Patients with Relasping Remitting Multiple Sclerosis who have had a Suboptimal Response to an Adequate Course of Disease- Modifying Treatment	Number Agreed	3	3	Date Agreed	31/07/2017	3	03/03/2017	3	Recruitment Finished
16/LO/0016	195795	A Phase 3, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching from Regimens consisting of Boosted Atazanavir or Darunavir plus either Emtricitabine/Tenofovir or Abacavir/Lamivudine to GS-9883/Emtricitabine/Tenofovir Alafena	Number Agreed	10	10	Date Agreed	31/05/2016	2	07/03/2017	2	Withdrawn By Sponsor
16/SC/0422	209437	A PHASE 2A STUDY OF TRC105 (WITH OPTION TO ADD STANDARD DOSE BEVACIZUMAB) IN PATIENTS WITH REFRACTORY GESTATIONAL TROPHOBLASTIC NEOPLASIA (GTN)	Number Agreed	2	2	Date Agreed	01/05/2018	0	31/07/2017	0	Withdrawn By Sponsor
15/SC/0306	176881	A phase 3,Randomized,Double-Blind,Placebo-Controlled Study of Ramacirumab plus Doxetacel vs Placebo plus Doxetacel in Patients with Locally Advanced or Unresectable or Metasthatic Urothelial Carcinoma Who Progressed or After Platinum-Based Therapy	Number Agreed	3	3	Date Agreed	01/02/2017	3	20/03/2017	3	Recruitment Finished
16/EM/0180	199125	A Multicentre Dose-Finding, Randomised, Double-Blind, Placebo-Controlled Study to Select the Daily Oral Dose of Estetrol (E4) for the Treatment of Vasomotor Symptoms in Post-Menopausal Women	Number Agreed	8	8	Date Agreed	21/09/2017	3	29/08/2017	3	Withdrawn By Sponsor
16/EM/0078	199717	Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter, Exploratory Phase IIa Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 Administered for 12 Weeks in Subjects with Idiopathic Pu	Number Agreed	1	1	Date Agreed	17/11/2016	0	31/01/2017	0	Recruitment Finished
16/EE/0195	200168	A randomized, double-blind phase 3 study of vadastuximab talirine (SGN-CD33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML)	Number Agreed	3	3	Not Available / Not Agreed			20/06/2017	1	Withdrawn By Sponsor

15/NW/0671	184963	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Enzalutamide in Subjects with Advanced Hepatocellular Carcinoma	Number Agreed	2	2	Not Available / Not Agreed			25/04/2017	2	Recruitment Finished
16/SC/0161	186322	A Phase III, Open-Label, Randomized Study Of Atezolizumab (Mpdl3280a, Anti-Pd-L1 Antibody) In Combination With Carboplatin Or Cisplatin + Pemetrexed Compared With Carboplatin Or Cisplatin + Pemetrexed In Patients Who Are Chemotherapy-Naive And Have S	Number Agreed	6	6	Date Agreed	01/07/2017	4	07/04/2017	4	Withdrawn By Sponsor
15/NI/0258	191587	A PERFORMANCE EVALUATION STUDY OF ARQUER'S MCM5 ELISA TEST TO AID IN THE DIAGNOSIS OF BLADDER CANCER	Number Agreed	130	130	Date Agreed	31/12/2016	295	28/02/2017	295	Recruitment Finished
15/LO/1879	186859	A Randomized, Open-label Study of Ponatinib Versus Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Resistance to Imatinib	Number Agreed	4	4	Date Agreed	15/12/2022	0	10/05/2017	0	Withdrawn By Sponsor
15/EM/0344	183906	A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Amatuximab in Combination with Pemetrexed and Cisplatin in Subjects with Unresectable Malignant Pleural Mesothelioma	Number Agreed	2	2	Date Agreed	31/10/2017	2	11/01/2017	2	Withdrawn By Sponsor
16/LO/0014	190759	A Prospective Multicenter Phase III Clinical Evaluation of the Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress Echocardiography with Dobutamine for the Diagnosis of Coronary Artery Disease	Range Agreed	10	12	Date Agreed	10/04/2017	12	17/04/2017	12	Recruitment Finished
13/NE/0005	100377	Product Surveillance Registry – A prospective, non-interventional registry providing continuing evaluation and periodic reporting of product safety, effectiveness and patient outcomes across Medtronic market-released products within diabetes, cardiac	Number Agreed	7	7	Date Agreed	28/04/2017	8	28/04/2017	8	Recruitment Finished
15/SC/0409	183061	Safety and Efficacy of Abicipar Pegol in Patients with Neovascular Age-related Macular Degeneration	Number Agreed	10	10	Date Agreed	03/06/2019	0	07/04/2017	0	Recruitment Finished
15/LO/1105	181406	A Randomized, Single-Blind, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose Levels of Imetelstat in Subjects with Intermediate-2 or High-Risk Myelofibrosis (MF) Relapsed/Refractory to Janus Kinase (JAK) Inhibitor	Number Agreed	3	3	Date Agreed	19/09/2016	0	10/04/2017	0	Withdrawn By Sponsor
14/LO/1834	165047	A Phase I randomised, placebo-controlled, double-blind, single and multiple ascending dose study of the tolerability and pharmacokinetics of GBT440 in healthy subjects and patients with Sickle Cell Disease	Range Agreed	4	6	Date Agreed	01/02/2017	6	01/02/2017	6	Recruitment Finished
14/NW/1427	166630	A Phase 3, Randomized Study Investigating the Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena) Compared to an Observational Cohort Control	Number Agreed	4	4	Date Agreed	13/12/2017	6	24/07/2017	6	Recruitment Finished